National Cancer Institute - U.S. National Institutes of Health - www.cancer.gov
National Cancer Institute - U.S. National Institutes of Health - www.cancer.gov
Clinical Trials at NIH Home

Clinical Trials by Cancer Site

AIDS-related Cancers/HIV Infection

The human immunodeficiency virus (HIV) attacks and weakens the body's immune system. Being infected with HIV does not mean that a person has AIDS. However, if left untreated, HIV infection can damage the immune system and progress to AIDS. AIDS is diagnosed in people with HIV if they develop an AIDS-defining illness (an illness that is very unusual in someone who is not infected with HIV) or if their CD4 white blood cells fall below a certain level. Some cancer types are more likely to occur in people who are infected with HIV. The most common types are Kaposi sarcoma and non-Hodgkin lymphoma.

Kaposi Sarcoma

There are a number of different types of Kaposi sarcoma (KS), a cancer that causes lesions (abnormal tissue) to grow under the skin, in the lining of the mouth, nose, and throat, or in other organs. The lesions are usually purple and are made of cancer cells, new blood vessels, and white blood cells. KS is different from other cancers in that lesions may begin in more than one place in the body at the same time.

Epidemic KS is the type that occurs in people with AIDS. Over time, epidemic KS spreads to other parts of the body and may cause fever, weight loss, or diarrhea. With new treatments for AIDS, KS has become less common in the United States, affecting only about 7 people per million each year.*

Non-Hodgkin lymphoma

Non-Hodgkin lymphoma (NHL) occurs in 4 percent to 10 percent of people with AIDS and tends to be aggressive in nature. It is a cancer that starts in the white blood cells of the lymph system, part of the body's immune system, and may spread to other organs. Primary central nervous system lymphoma (PCNSL), a disease in which cancer cells form in the lymph tissue of the brain and/or spinal cord, occurs in 20 percent of all NHL cases in AIDS patients.

*American Cancer Society

AIDS-related Cancers/HIV Infection Clinical Trials

The Center for Cancer Research (CCR), NCI's largest Division doing research on campus, conducts AIDS-related/HIV infection clinical trials at the NIH Clinical Center in Bethesda, Md. NCI accepts referrals for these trials through its Clinical Trials Referral Office at 1-888-NCI-1937 (1-888-624-1937).

NCI is currently conducting the following trials for patients with AIDS-related cancer/HIV infection. Click on the trials below for additional details, including summaries of eligibility criteria, study outline, and information on how to contact the principal investigators and their staff directly.


  
Trial and Protocol Number
AIDS Related Cancers
Phase II
AIDS-Related Primary Central Nervous System Lymphoma: A Phase II Pilot Study of High-Dose Intravenous Methotrexate With Rituximab Leucovorin Rescue and Highly Active Antiretroviral Therapy
NCI-06-C-0051

Principal Investigator:Referral Contact:
Robert YarchoanKaren Aleman
301-496-8959301-496-8959
1-800-243-2732 ext. 4 (Toll Free)
alemank@mail.nih.gov
Short-Course EPOCH-Rituximab in Untreated CD-20+ HIV-Associated Lymphomas
NCI-01-C-0030

Principal Investigator:Referral Contact:
Wyndham H. WilsonNicole Grant
301-435-2415301-594-2947
grantn@mail.nih.gov
No Phase
Targeted Oncolytic Virotherapy and Natural History Study of KSHV-Associated Multicentric Castleman’s Disease With Laboratory and Clinical Correlates of Disease Activity
NCI-04-C-0275

Principal Investigator:Referral Contact:
Robert YarchoanKaren Aleman
301-496-8959301-496-8959
1-800-243-2732 ext. 4 (Toll Free)
alemank@mail.nih.gov


  
Trial and Protocol Number
HIV Infection
Phase I
A Pilot Study to Investigate the Safety and Immunogenicity of a Peptide Vaccine for HIV Infected HLA-A2 Individuals Designed to Impede Development of Antiretroviral Resistance
NCI-06-C-0211

Principal Investigator:Referral Contact:
Robert YarchoanKathy Wyvill
301-496-8959301-496-8959
1-800-243-2732 ext. 4 (Toll Free)
wyvillk@mail.nih.gov


  
Trial and Protocol Number
Kaposi Sarcoma
Phase II
Pilot Study of Liposomal Doxorubicin Combined With Bevacizumab Followed by Bevacizumab Monotherapy in Adults With Advanced Kaposi’s Sarcoma
NCI-09-C-0130

Principal Investigator:Referral Contact:
Robert YarchoanKathy Wyvill
301-496-8959301-496-8959
1-800-243-2732 ext. 4 (Toll Free)
wyvillk@mail.nih.gov
Phase I
Phase I and Pharmacokinetic Study of BAY 43-9006 (Sorafenib) in Patients With Kaposi’s Sarcoma
NCI-06-C-0083

Principal Investigator:Referral Contact:
Robert YarchoanKathy Wyvill
301-496-8959301-496-8959
1-800-243-2732 ext. 4 (Toll Free)
wyvillk@mail.nih.gov


Back to Top
Health and Human Services National Institutes of Health National Cancer Institute USA.gov National Cancer Institute Clinical Trials at NIH - Be part of the cure